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Background: The mechanisms of generation and progression of
multicentric lung adenocarcinoma (AD), bronchioloalveolar carci-
noma (BAC), and atypical adenomatous hyperplasia (AAH) in the
peripheral lung is not well known. In this study, we analyzed
epidermal growth factor receptor (EGFR) mutations in the cases of
multicentric AD, BAC, and AAH to reveal the role of EGFR
mutation in their generations and progressions.
Method: Ninety-seven AAH, BAC, or AD lesions less than 3 cm in
size in 26 patients were surgically resected. Of these, EGFR muta-
tions of the nodules with the highest and the second highest grade of
histologic malignancy were examined in each patient by using the
peptide nucleic acid-locked nucleic acid polymerase chain reaction
(PNA-LNA PCR) clamp method.
Results: EGFR mutations could be examined in 48 nodules in the 26
patients. The EGFR mutations were found more frequently in
lesions with higher histologic malignancy, ie, 9 of 10 ADs (90%), 16
of 28 BACs (57%), and one of 10 AAHs (10%). In 22 patients who
could be examined of EGFR mutations for the two lesions in each
patient, only two patients (9%) had the same mutation patterns
between the two lesions, whereas 15 patients (68%) had the different
statuses and the remaining five (23%) had no mutations.
Conclusion: Our data demonstrated that EGFR mutations seem to
contribute to the acquisition of malignant potential in the AAH-AD
sequence and occur independently in each lesion and in the cases of
multicentric AD, BAC, and AAH.
(J Thorac Oncol. 2008;3: 467–471)
Recent advances in high-resolution computed tomographyand the prevalence of CT screening for lung cancer have
increased the detection of multiple ground-glass opacity (GGO)
nodules,1–4 which are often atypical adenomatous hyperplasia
(AAH), bronchioloalveolar carcinoma (BAC), and adenocarci-
noma (AD). However, the mechanisms of generation and pro-
gression of these multiple lesions are still unknown.
The concepts of multistep carcinogenesis during which
genetic mutations are sequentially accumulated resulting in the
development of invasive tumors have been well established in a
number of cancers, including colon and breast cancers.5,6 Al-
though a hypothesis of multistep carcinogenesis has been also
proposed for lung AD, ie, AD develops from AAH to invasive
AD through BAC,7 the signals that cause to either transform into
invasive AD or to remain AAH or BAC are still unknown.
It has been reported that ADs with BAC features
frequently have epidermal growth factor receptor (EGFR)
mutations.8,9 Recently, the possibility of significant role of
EGFR mutation in the carcinogenesis of lung AD was also
described. Tang et al. showed that EGFR mutation were
frequently observed in normal epithelium of patients with
EGFR mutant lung AD and described that EGFR mutation
could occur in the early step of AD development.10 Ji et al.
showed a close relationship between EGFR mutation and
carcinogenesis of lung AD in the experiments on the trans-
genic mice.11 From these reports, we speculate that AAH or
BAC lesions in patients with multiple AAH, BAC, and AD
lesions could already have EGFR mutations. If the EGFR
mutations occurred in an early step of AD development,
EGFR tyrosine kinase inhibitors (TKIs) could be one of the
treatments for patient with multiple AAH, BAC, and AD
lesions, because they are frequently effective for AD with
EGFR mutations.12,13
In this study, to investigate the role of EGFR mutations
in generation and progression of multicentric AD, BAC, and
AAH lesions, we examined the EGFR mutations in patients
with these lesions.
PATIENTS AND METHODS
Patients
Between January 1999 and December 2006, 276 pa-
tients with AD, BAC, or AAH lesions underwent surgical
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resection in Kumamoto University Hospital. Of these, 30
patients had multiple AAH, BAC, and AD lesions, whereas
the 246 patients had single lesion. In the 30 patients with
multiple lesions, to rule out intrapulmonary metastasis, two
patients with moderately or poorly differentiated AD and two
patients with lesions more than 3 cm in size were excluded
from this study. As a result, 26 patients with multiple AAH,
BAC, and AD lesions that showed GGO images on CT were
selected for this study. The pathologic diagnoses were made
by two different pathologists (Y.H. and K.I.)according to the
1999 World Health Organization histologic classification.14,15
The multiple lesions in the present case were denied as
metastatic ones, according to the criteria of Martini and
Melamed.16 None of the patients received adjuvant chemo- or
radiotherapy before surgery.
The study protocol for examining EGFR mutation from
the resected lesions was approved by the Ethics Committee of
Kumamoto University Hospital in May 2005. Written in-
formed consent was obtained from all patients for investiga-
tion of their EGFR mutations of tumors. The tumors with the
highest and the second highest grade of histologic malig-
nancy were defined as the first and second tumors, respec-
tively, in each patient. Then, the DNA extracted from the first
and the second tumors was investigated for EGFR mutations.
Detection of EGFR Mutations
We analyzed exons 18, 19, and 21, because most
mutations were known to be clustered in these exons.17
Because most of the examined nodules were less than 2 cm
and the amount of extracted DNA was relatively small, the
EGFR mutation statuses were analyzed with the use of
peptide nucleic acid-locked nucleic acid polymerase chain
reaction (PNA-LNA PCR) clamp methods, which was re-
ported to be more sensitive than conventional direct sequenc-
ing.18,19 Surgically resected specimens were fixed with for-
malin and embedded in paraffin. All sections were cut from
paraffin blocks at a thickness of 5 m. DNA extraction and
analysis of EGFR mutations were performed by Mitsubishi
Kagaku Bio-chemical Laboratories Inc (Tokyo, Japan). Tu-
mor cells were visually dissected, and samples were incu-
bated in 200 L of lysis buffer (10 mMTris–HCl pH 8.0, 1
mM EDTA, 0.5% SDS) with 40 g of glycogen and 2 L of
proteinase K (20 mg/mL) and incubated at 56°C overnight.
DNA was purified by phenol and chloroform extraction and
dissolved in 20 L TE (10 mM Tris–HCl pH 8.0, 1 mM
EDTA). The details of PNA-LNA clamp methods and the
design of PCR primers was followed by Nagai et al.19 Briefly,
all PCR reaction solutions (25 L) were based on the Basic
Mixture containing 25 mmol/L TAPS (pH 9.3), 50 mmol/L
KCl, 2 mmol/L MgCl2, 1 mmol/L 2-mercaptoethanol, 200
mol/L each of deoxynucleotide triphosphates, and 1.25
units of Takara Ex TaqHS (Takara Bio, Shiga, Japan). For
conventional PCR, PCR primers (200 nmol/L each) were
added to the Basic Mixture. For PNA-LNA PCR clamp, PCR
primers (200 nmol/L each), fluorogenic probes (100 nmol/L
each), and a PNA clamp primer (5 mol/L) were added to the
Basic Mixture. The real-time amplification monitoring for
both conventional and the PNA-LNA PCR clamp were done
using Smart Cycler II (Cepheid, Sunnyvale, CA). PCR cy-
cling was a 30-second hold at 95°C followed by 45 cycles of
95°C for 3 seconds and 62°C (exon 18 and 19) or 56°C (exon
21) for 30 seconds. Nested PCR for the PNA-LNA PCR
clamp was done using the same reaction conditions except
that the inner primers and 1 L of a 1:106 dilution of the first
PCR reaction were used.
Detection of K-ras mutations
We also analyzed the mutation of K-ras exon 2 in the
same extracted DNA samples. We used the enriched PCR
methods to analyze the K-ras mutations, which was reported
to be able to detect K-ras mutation from small amount of
DNA samples.20
Statistical Analysis
All values in the text and tables are given as mean 
SD. Category data were compared using the Fisher exact test.
The numeric data were analyzed for significance using the
two-tailed Student t test. Bonferroni test was used to deter-
mine significance for comparisons among three parts. Values
of p  0.05 were accepted as significant.
RESULTS
Clinicopathological Characteristics
Clinicopathological characteristics of the 26 patients
with multiple AAH, BAC, and AD lesions are shown in Table
1. There were 6 men and 20 women. Twenty patients (77%)
were never smokers. Two patients (8%) had a familial history
of lung cancer within the second degree of kinship. The
number of resected lesions in each patient was 1 in 3 patients,
2 in 12, 3 in 4, 4 in 2 and more than 5 (up to 27) in 5.
TABLE 1. Patient’s Characteristics
Mean age (yr; range) 65 (49–79)
Sex
Male 6
Female 20
Smoking status
Smoker 6
Never smoker 20
Number of lesions in CT
2 8
3 4
4 3
5 11
Number of resected lesions
1 3
2 12
3 4
4 2
5 5
Location
Bilateral 10
Unilateral 16
Total 26
CT, computed tomography.
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Pathologic diagnoses of the 97 resected nodules were AAH in
34, BAC in 52, and AD in 10. All of the ADs were well
differentiated one with BAC or AAH features except for one,
which showed a pure papillary pattern. The mean size was
5  3 mm in AAH, 9  8 mm in BAC, and 16  8 mm in
AD. There was a significant difference in the mean sizes
among the three groups (p  0.05). Of the 26 patients, two
patients had multiple AAH lesions. Six patients had multiple
BAC lesions. Eight patients had multiple BAC and AAH
lesions. Ten patients had AD with BAC or AAH or both. Of
the 97 lesions, 54 were resected by lobectomy, 13 by seg-
mentectomy, and 30 by wedge resection. Bilateral lesions
were resected in 10 patients, seven of whom underwent
simultaneous bilateral resections. Although lymph node dis-
sections or samplings were performed in all patients, none of
the patients had lymph node metastasis. All patients are alive
without recurrence (mean observation period: 661 days) ex-
cept for one patient, who died of another disease. In 10
patients, all of lesions could not be resected because of too
many lesions, although all of the nonresected nodules have
not grown after surgery.
Mutation Analysis
In 4 of the 26 patients, only one lesion could be
examined for EGFR mutations because only one nodule was
resected in two patients and the second tumor were too small
to extract sufficient amount of DNA in two patients. As a
result, EGFR mutations could be examined for 48 nodules in
the 26 patients. EGFR mutations were detected in one of the
10 AAHs (10%), 16 of the 28 BACs (57%), and 9 of the 10
ADs (90%) (Table 2). Thirty-eight lesions of AD or BAC
harbored EGFR mutations more frequently than 10 AAH
lesions (p  0.01). AD harbored EGFR mutations more
frequently than BAC with marginal significance (p  0.06).
One AD without EGFR mutation showed a pure papillary
pattern without BAC features (Case 8 in Table 3). One AAH
with EGFR mutation was histologically high grade one (Case
17 in Table 3).
Of the 48 lesions, 26 (54%) harbored EGFR mutations.
The type of mutations in these 26 lesions was exon 21 L858R
in 15 lesions (58%), exon 19 deletions in 10 (38%), and exon
21 L861Q in one (4%). Tables 3 and 4 show the mutation
statuses of the lesions of the 22 patients who could be
examined for the presence of EGFR mutations in both first
and second tumors, two patients (9%) showed the same
pattern of mutations in each lesion. Fifteen patients (68%)
showed different mutational statuses of mutations among the
lesions, of whom five patients showed different patterns of
mutations between the two lesions and 10 patients had EGFR
mutations in only one of the two lesions. Five patients (23%)
showed no mutation in both lesions.
K-ras mutations were detected in one AAH (10%) and
one BAC (4%). Both of them were transversion that changes
G to T at codon 12. These K-ras mutations were not over-
lapped with the EGFR mutations.
DISCUSSION
It has been reported that ADs with BAC features harbor
EGFR mutations frequently, ie, 9 of 18 (50%) by Blons et
al.,8 and 14 of 21 (66%) by Hsieh et al.9 The significant high
rate of EGFR mutation was also reported in ADs of East
Asian patients (270 of 563, 48%), females (203 of 411, 49%),
and nonsmokers (232 of 433, 54%).21 Although the mutation
rate of ADs in our study was 90% (9 of 10), which was higher
than those in previous reports, it could be because of the
following reasons: (1) All of the patients were East Asian; (2)
Twenty of the 26 patients (77%) were female; (3) Twenty of the
26 patients (77%) were nonsmokers; and (4) Nine of the 10 ADs
(90%) were well differentiated AD with BAC features.
Our result showed that the EGFR mutation patterns of
the first and second tumors were same in only 2 of the 22
patients (9%) and the mutation statuses were different in 15
of the 22 patients (68%). This result demonstrated that EGFR
mutations would be independently acquired after multicentric
generation of the AAH, BAC, and AD lesions.
A hypothesis of multistep carcinogenesis has been
proposed for lung AD, which develops from AAH to invasive
AD through BAC.7 We expected that EGFR mutations might
occur in an early step of the AAH-AD sequence, and there-
fore that the mutation might frequently be detected already in
AAH or BAC in patients with multiple AAH, BAC, and AD
lesions. However, our results showed that most AAHs did not
have EGFR mutations and that BACs had the mutations less
frequently than ADs. This result corresponded to that of
Yoshida et al., who examined EGFR mutations mostly in
solitary AAH, BAC, and AD lesions.22 We therefore consider
that the EGFR mutations would not cause the occurrence of
multiple AAH, BAC, and AD lesions and would be acquired
independently after multicentric generation of the lesions,
and contribute to acquirement of malignant potentials during
AAH-AD sequence.
The K-ras mutation in AAH was reported to be shown
in 8 of 30 lesions (27%) by Yoshida et al.22 and 13 of 40
(32%) by Sakamoto et al.,23 of which frequency was higher
than the one of 10 (10%) in our study. Although the reason of
relatively low frequency of K-ras mutation in our study is not
clear, it might be a character of our study with multiple
neoplastic lesions.
In 10 of the 26 patients, all of the lesions could not be
resected because of too many lesions. Because EGFR-TKIs
would be effective for AD lesions with EGFR muta-
tions,12,13,24 we first expected that EGFR-TKIs could be
effective for not only AD but also BAC or AAH in these
patients. However, our results showed that the EGFR muta-
TABLE 2. EGFR Mutations in Each Histological Type
Histological
Type
Number of Nodules (%)
Total
With
Mutations
Without
Mutations
AAH 1 (10%) 9 (90%) 10
BAC 16 (57%) 12 (43%) 28
AD 9 (90%) 1 (10%) 10
Total 26 (54%) 22 (46%) 48
EGFR, epidermal growth factor receptor; AAH, atypical adenomatous hyperplasia;
BAC, bronchioloalveolar carcinoma; AD, adenocarcinoma.
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tions were rare in AAH and were less frequent in BAC than
in AD. Therefore, EGFR-TKIs might not be effective for
AAH and BAC in the patients with multiple AAH, BAC, and
AD lesions.
Although CT guided needle aspiration biopsy is a
minimally invasive method for histologic diagnosis, it has
some difficulties to differentiate boundary lesions. Our study
showed that 90% of ADs in multiple GGO nodules had
EGFR mutations, whereas 90% of AAHs did not. Because
PNA-LNA PCR clamp method can detect EGFR mutations of
small tumor tissues with higher sensitivity than the conven-
tional direct sequencing,18,19 we believe that the EGFR mu-
tation analysis in the specimens obtained by needle biopsy
would contribute to a pathologic diagnosis and prediction of
malignant grade of GGO nodules. For example, when the
EGFR mutations were positive in biopsy specimens of GGO
nodules, which were suspected of AAH or BAC with histo-
logic findings, surgical resection could be recommended
because of high possibility of high grade of BAC. When
EGFR mutations were negative for GGO nodules, which
were suspected of AAH or BAC with histologic findings,
follow-up could be one of the choices because of high
possibility of AAH or low grade of BAC.
In conclusion, EGFR mutations independently occurred
after mulicentric generation of lung cancers. In addition, there
was close relationship between the histologic malignancy
grade and EGFR mutations in patients with multiple AAH,
BAC, and AD lesions. Although EGFR mutations would not
to be involved in generation of multiple AAH, BAC, and AD
lesions, they seem to contribute to the acquisition of malig-
nant potential in the AAH-AD sequence. We believe that our
results would contribute to a guideline of clinical manage-
ment of patients with multiple GGO nodules.
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